An FDA panel has voted against AstraZeneca's breast cancer candidate drug, citing concerns over its benefit-risk profile. The drug in question is a combination therapy that includes camizestrant, although the exact outcome of the vote and the FDA's next steps are unclear. The FDA had previously flagged concerns about the drug ahead of the advisory committee meeting.